Browsing by Author "Ibrahim, Sherif A."

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    HS2ST1‐dependent signaling pathways determine breast cancer cell viability, matrix interactions and invasive behavior
    (wiley online library, 6/23/2020) Vijaya Kumar, Archana; Brézillon, Stéphane; Untereiner, Valérie; Dhruvananda Sockalingum, Ganesh; Kumar Katakam, Sampath; Taha Mohamed, Hossam; Kemper, Björn; Greve, Burkhard; Mohr, Benedikt; Ibrahim, Sherif A.; Goycoolea, Francisco M.; Kiesel, Ludwig; Pavão, Mauro S.G.; Motta, Juliana M.; Götte, Martin
    Heparan sulfate proteoglycans (HSPGs) act as signaling coreceptors by interactions of their sulfated glycosaminoglycan chains with numerous signaling molecules. In breast cancer, the function of heparan sulfate 2‐O‐sulfotransferase (HS2ST1 ), the enzyme mediating 2‐O‐sulfation of HS, is largely unknown. Hence, a comparative study on the functional consequences of HS2ST1 overexpression and siRNA knockdown was performed in the breast cancer cell lines MCF‐7 and MDA‐MB‐231. HS2ST1 overexpression inhibited matrigel invasion, while its knockdown reversed the phenotype. Likewise, cell motility and adhesion to fibronectin and laminin were affected by altered HS2ST1 expression. Phosphokinase array screening revealed a general decrease in signaling via multiple pathways. Fluorescent ligand binding studies revealed altered binding of fibroblast growth factor 2 (FGF‐2) to HS2ST1 expressing cells compared to control cells. HS2ST1 overexpressing cells showed reduced MAPK signaling responses to FGF‐2, and altered expression of EGFR, E‐cadherin, Wnt‐7a and Tcf4. The increased viability of HS2ST1 depleted cells was reduced to control levels by pharmacological MAPK pathway inhibition. Moreover, MAPK inhibitors generated a phenocopy of the HS2ST1 ‐dependent delay in scratch wound repair. In conclusion, HS2ST1 modulation of breast cancer cell invasiveness is a compound effect of altered E‐cadherin and EGFR expression, leading to altered signaling via MAPK and additional pathways